Evidence‑Based Management of Snakebite Envenomation

Prehospital Recommendations

• Activate emergency medical services immediately and transport the patient to a hospital capable of providing antivenom and mechanical ventilation; avoid traditional harmful interventions such as tourniquets, incisions, suction, ice, or electric therapy. (American Heart Association 2024 guideline – strong recommendation) 1
• Call emergency services without delay for any suspected venomous snakebite and arrange rapid transport to a facility that stocks antivenom. (American Heart Association 2024 – Class I recommendation) 1
• Remove rings, watches, or tight jewelry from the bitten limb before swelling develops; although not formally studied, this is considered a reasonable first‑aid measure. (American Heart Association 2024 – expert consensus) 1
• Minimize the patient’s physical activity because ambulation can increase systemic venom absorption; however, transport should not be postponed to achieve complete immobilization. (American Heart Association 2024 – Class I recommendation) 1
• Immobilize the bitten limb with a simple splint or bandage and keep it at rest to limit systemic venom uptake. (Praxis Medical Insights 2026 – moderate evidence) 2

Contraindicated First‑Aid Measures

• Do not apply tourniquets; systematic reviews demonstrate they worsen local tissue injury and provide no benefit. (American Heart Association 2024 – Level A evidence) 1
• Do not use ice or cryotherapy; case reports have documented tissue damage from aggressive cooling. (American Heart Association 2024 – Level C evidence) 1
• Do not perform suction (with or without incision); it is ineffective at removing venom and may cause additional tissue trauma. (American Heart Association 2024 – Level C evidence) 1
• Do not apply electric shock therapy; systematic reviews show it is ineffective and potentially harmful. (American Heart Association 2024 – Level A evidence) 1
• Do not use pressure‑immobilization bandages for North American bites; >95 % of envenomations involve cytotoxic snakes, and studies reveal low correct‑application rates even among clinicians. (American Heart Association 2024 – Level B evidence) 1

Hospital Definitive Care

• Polyvalent antivenom is the definitive therapy and must be administered intravenously in the emergency department. (Praxis Medical Insights 2026 – strong recommendation) 2
• Systemic envenomation signs to monitor include hypotension, bleeding, muscle fasciculations progressing to paralysis (elapid bites), and local tissue injury with erythema, warmth, pain, and swelling (crotalid bites). (American Heart Association 2024 – Class I recommendation) 1

Species‑Specific Considerations

• Crotalid snakes (rattlesnakes, copperheads, water moccasins) account for >95 % of North American bites; their venom is primarily cytotoxic, causing local tissue necrosis, hypotension, bleeding, and fasciculations. Bite wounds are typically red, hot, tender, and swollen. (American Heart Association 2024 – expert consensus) 1
• Elapid snakes (coral snakes, kraits) deliver primarily neurotoxic venom without significant local tissue damage. Neurotoxic paralysis can progress to respiratory failure within 1.5–6.5 hours, making rapid transport essential, and the receiving facility must have mechanical ventilation capability. (Praxis Medical Insights 2026 – moderate evidence) 2

Common Pitfalls to Avoid

• Do not delay transport by attempting elaborate first‑aid measures; rapid hospital arrival is the priority. (American Heart Association 2024 – Class I recommendation) 1
• Do not apply North American pit‑viper (crotalid) protocols to elapid bites, as the venom mechanisms differ fundamentally. (Praxis Medical Insights 2026 – expert consensus) 2
• Do not underestimate the need for prolonged observation even after apparently mild bites; delayed progression of envenomation is documented. (American Heart Association 2024 – Class I recommendation) 1

Clinical Assessment and Management of Snakebite Envenomation Without Laboratory Support

Local Clinical Evaluation

• Progressive edema – Measuring the spread of swelling from the bite site toward proximal joints (e.g., >5 cm or crossing a joint) is a key indicator of envenomation severity; viper bites typically produce red, hot, tender, and markedly swollen wounds. 3, 4
• Erythema and increased temperature – The extent of redness and warmth around the bite area correlates with local tissue injury and helps grade severity. 3

Systemic Clinical Evaluation

• Neurological signs – Presence of ptosis markedly raises the likelihood of severe systemic envenoming (likelihood ratio ≈ 3.8); accompanying findings such as muscle fasciculations, progressive paralysis, and respiratory difficulty further support a severe classification. 3
• Cardiovascular signs – Hypotension, shock manifestations, and tachycardia are strong clinical predictors of systemic toxicity. 3

Critical Management Recommendations

• Immediate emergency activation and transport – Promptly calling emergency services and moving the patient to a facility with antivenom is the highest‑priority action, regardless of the completeness of the clinical classification. 3, 4
• Continuous observation for delayed progression – Envenomation can evolve from mild to severe over time; ongoing monitoring is essential even after an apparently minor bite. 3
• Removal of constrictive objects – Rings, watches, jewelry, and similar items should be taken off before edema develops enough to cause constriction. 3, 4
• Avoidance of harmful first‑aid measures – Tourniquets, ice, suction, incisions, and electrical therapy are contraindicated because they can worsen tissue damage. 3, 4
• Limit physical activity but do not delay transport – Ambulation can increase systemic venom absorption, yet transport to definitive care must not be postponed to achieve complete immobilization. 3, 4

Severity Thresholds Requiring Antivenom

• Any systemic sign (e.g., ptosis, fasciculations, hypotension, bleeding) indicates moderate‑to‑severe envenomation and warrants antivenom administration. 4

Antibiotic Management of Cellulitis After Snake Bite

Initial Assessment and Triage

• Emergency activation is required for any venomous or possibly venomous snake bite because antivenom is the definitive treatment and must be given in a hospital setting. 5
• The presence of cellulitis signals local cytotoxic injury from crotalid (pit‑viper) venom, manifested by erythema, warmth, tenderness, and swelling. 6

First‑Line Antibiotic Selection (Streptococcal Coverage)

• For mild‑to‑moderate cellulitis, oral beta‑lactam agents such as penicillin, amoxicillin, cephalexin, dicloxacillin, or amoxicillin‑clavulanate are recommended as first‑line therapy. (Evidence: prospective cohort) 7
• For severe cellulitis with systemic features, intravenous cefazolin or oxacillin provides adequate streptococcal coverage and achieved a 96 % success rate in prospective studies. (Evidence: prospective study) 8
• A treatment duration of 5 days is as effective as 10 days when clinical improvement is evident by day 5. (Evidence: randomized comparison) 7

Antibiotic Choice in Penicillin‑Allergic Patients

• Clindamycin is the preferred alternative for patients with penicillin allergy, offering coverage of both streptococci and staphylococci. (Evidence: prospective cohort) 8

Indications for Adding MRSA Coverage

• Routine MRSA‑directed therapy is not required for typical cellulitis, even in regions with high MRSA prevalence. (Evidence: guideline consensus) 7
• MRSA coverage should be added when any of the following are present:

MRSA‑Active Treatment Options

• Intravenous: vancomycin, daptomycin, linezolid, or telavancin. (Evidence: guideline consensus) 8
• Oral: doxycycline, clindamycin, or trimethoprim‑sulfamethoxazole (SMX‑TMP). (Evidence: guideline consensus) 7
• When doxycycline or SMX‑TMP is used, a beta‑lactam (e.g., penicillin, cephalexin, or amoxicillin) must be added because these agents have uncertain activity against beta‑hemolytic streptococci. (Evidence: guideline consensus) 8
• A double‑blind study demonstrated that SMX‑TMP plus cephalexin was no more effective than cephalexin alone for pure cellulitis. (Evidence: double‑blind trial) 7

Tetanus Prophylaxis

• Standard tetanus prophylaxis should be administered for snake‑bite wounds, following routine wound‑management protocols. (Evidence: guideline consensus) 7

Monitoring of Clinical Response

• Serial assessment of erythema, warmth, and tenderness provides information on both envenomation severity and antibiotic effectiveness. (Evidence: guideline consensus) 8
• An increase in local inflammation during the first 24–48 hours after starting antibiotics may occur due to pathogen lysis and does not indicate treatment failure. (Evidence: guideline consensus) 7
• Persistent fever, expanding erythema, or systemic deterioration after 48–72 hours warrants reassessment and consideration of MRSA‑directed therapy. (Evidence: guideline consensus) 8

Adjunctive Measures

• Elevating the affected extremity accelerates recovery by promoting drainage of edema and inflammatory mediators. (Evidence: guideline consensus) 7
• Remove rings and other constricting jewelry before swelling develops. (Evidence: guideline consensus) 5
• Limit physical activity to reduce systemic venom absorption, but do not delay transport to definitive care. (Evidence: guideline consensus) 9
• Systemic corticosteroids (e.g., prednisone 40 mg daily for 7 days) may be considered in non‑diabetic adults, although supporting evidence is weak. (Evidence: weak) 7

Common Pitfalls to Avoid

• Do not postpone antivenom administration while treating cellulitis; antivenom remains the definitive therapy for envenomation. (Evidence: guideline consensus) 5
• Do not routinely add MRSA coverage in non‑purulent cellulitis; beta‑lactam monotherapy succeeds in approximately 96 % of cases. (Evidence: prospective study) 8
• Do not employ tourniquets, suction, incision, or electric shock, as these interventions worsen outcomes. (Evidence: guideline consensus) 6
• Do not use pressure‑immobilization bandages for North American snake bites, because >95 % involve cytotoxic venom where such bandaging may increase tissue injury. (Evidence: guideline consensus) 9

Recurrence Prevention (When Applicable)

• Address predisposing factors such as tinea pedis, venous insufficiency, lymphedema, and skin‑barrier disruption to reduce the risk of recurrent cellulitis. (Evidence: guideline consensus) 8